Silence Therapeutics plcSLNEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.
SLN Q1 FY2024 Key Financial Metrics
Revenue
$15.7M
Gross Profit
$12.9M
Operating Profit
$-5.6M
Net Profit
$-2.3M
Gross Margin
82.2%
Operating Margin
-35.6%
Net Margin
-14.7%
YoY Growth
N/A
EPS
$-0.02
Silence Therapeutics plc Q1 FY2024 Financial Summary
Silence Therapeutics plc reported revenue of $15.7M for Q1 FY2024, with a net profit of $-2.3M (-14.7% margin). Cost of goods sold was $2.8M, operating expenses totaled $18.5M.
Key Financial Metrics
| Total Revenue | $15.7M |
|---|---|
| Net Profit | $-2.3M |
| Gross Margin | 82.2% |
| Operating Margin | -35.6% |
| Report Period | Q1 FY2024 |
Income Statement
| Q1 2024 | |
|---|---|
| Revenue | $15.7M |
| YoY Growth | N/A |
Balance Sheet
| Q1 2024 | |
|---|---|
| Assets | N/A |
| Liabilities | N/A |
| Equity | $156.8M |
Cash Flow
| Q1 2024 | |
|---|---|
| Operating CF | $-9.1M |